Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: Nested case-control study

BMJ (Online)

Volumn 345, Issue 7866, 2012, Pages

  Campbell, Robert J ^a,b,c   Gill, Sudeep S ^a,b,d   Bronskill, Susan E ^b,e   Paterson, J Michael ^b,e,f   Whitehead, Marlo ^a,b   Bell, Chaim M ^b,e,g,h  

^a QUEEN S UNIVERSITY   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c Hotel Dieu and Kingston General Hospitals   (Canada)

^d St Mary's of the Lake Hospital   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ACUTE HEART INFARCTION; AGED; ARTICLE; BRAIN ISCHEMIA; CANADA; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VENOUS THROMBOEMBOLISM; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HEART FAILURE; HEART INFARCTION; INTRAVITREAL DRUG ADMINISTRATION; RETINA DISEASE; RISK FACTOR; STATISTICAL MODEL; STROKE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HUMANS; INTRAVITREAL INJECTIONS; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; ONTARIO; RETINAL DISEASES; RISK FACTORS; STROKE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENOUS THROMBOEMBOLISM;

EID: 84864452615     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4203     Document Type: Article

References (57)

1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-95. (Pubitemid 38328641)
2. Cruess A, Zlateva G, Xu X, Rochon S. Burden of illness of neovascular age-related macular degeneration in Canada. Can J Ophthalmol 2007;42:836-43.
3. Javitt JC, Zhou Z, Maguire MG, Fine SL, Willke RJ. Incidence of exudative age-related macular degeneration among elderly Americans. Ophthalmology 2003;110:1534-9. (Pubitemid 36962485)
4. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17.
5. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration - a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-46.
6. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
8. CATT Research Group, Martin D, Maguire M, Ying G, Grunwald J, Fine S, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
9. Kamba T, McDonald D. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788.
10. Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, Blanco-Colio LM, Lorenzo O, Egido J. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration. Surv Ophthalmol 2009;54:339-48.
11. Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncology 2009;4:67-76.
12. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 2009;148:647-56.
13. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9. (Pubitemid 47299901)
14. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011;29:632-8.
15. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277.
16. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33. (Pubitemid 40270359)
17. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-44. (Pubitemid 29446822)
18. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70. (Pubitemid 44547437)
19. Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ 2010;340:c2459.
20. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 2009;116:362.
21. Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; published online 1 May.
22. Liew G, Mitchell P, Gillies MC, Wong TY, Rosenfeld PJ, Brown DM, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2007;356:747.
23. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments. JAMA 2008;300:2417-9.
24. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-9.
25. A summary of studies on the quality of health care administration databases in Canada. In: Goel V, Williams JI, Anderson GM, Blackstien-Hirsch P, Fooks C, Naylor D, eds. Patterns of health care in Ontario: the ICES practice atlas. 2nd ed. Canadian Medical Association, 1996:339-45 (available at www.ices.on.ca/file/Practice2-appendix.pdf).
26. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003;10:67-71. (Pubitemid 37028596)
27. Juurlink DN, Preyra C, Croxford R, Chong A, Austin P, Tu J, et al. Canadian Institute for Health Information discharge abstract database: a validation study. ICES investigative report. Institute for Clinical Evaluative Sciences, 2006 (available at www.ices.on.ca/file/CIHI-DAD-Reabstractors-study. pdf).
28. Gruneir A, Bell CM, Bronskill SE, Schull M, Anderson GM, Rochon PA. Frequency and pattern of emergency department visits by long-term care residents - a population-based study. J Am Geriatr Soc 2010;58:510-7.
29. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SLT, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 2009;169:867.
30. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6. (Pubitemid 41103345)
31. Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol 2010;128:359-62.
32. Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, et al. Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research. Med Care 2005;43:182-8. (Pubitemid 40222637)
33. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64. (Pubitemid 33000813)
34. Bell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Gruneir A, et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. JAMA 2009;301:1991.
35. Tu K, Campbell NRC, Chen ZL, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative databases in identifying patients with hypertension. Open Medicine 2007;1:e18.
36. Breslow N, Day N. Fitting models to continuous data. 82nd ed. IARC Scientific Publications, 1987:178-229.
37. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. John Wiley and Sons, 2005:811-29.
38. Breslow N, Lubin J, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc 1983;78:1-12.
39. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
40. Liddell F, McDonald J, Thomas D. Methods of cohort analysis: appraisal by application to asbestos mining. J R Stat Soc Ser A 1977;140:469-91.
41. Institute for Clinical Evaluative Sciences. Ontario stroke evaluation report 2011: improving system efficiency by implementing stroke best practices. Supplementary materials. www.ices.on.ca/webpage.cfm?site-id=1&org-id= 68&morg-id=0&gsec-id=0&item-id=6813&type=report.
42. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I-4,I-8.
43. Public Health Agency of Canada. Tracking heart disease and stroke in Canada. 2009. www.phac-aspc.gc.ca/publicat/2009/cvd-avc/index-eng.php.
44. French DD, Margo CE. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina 2011;31:1036-42.
45. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. N Engl J Med 2011;364:1966-7.
46. Al-Qureshi S, Shaikh S. Intravitreous bevacizumab adult safety data: the evidence so far. Clin Experiment Ophthalmol 2012;40:3-5.
47. Gower EW, Cassard S, Chu L, Varma R, Klein R. Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration [abstract 6644]. ARVO Visionary Genomics, Fort Lauderdale, Florida, May 2011 (available at www. abstractsonline.com/Plan/ViewAbstract. aspx?sKey=3a667d20-f42d-421e-a859-e1b680de80ed&cKey=4e534aee-b678-4b9d-91dc- 20a9d6ae0c56&mKey=%7b6F224A2D-AF6A-4533-8BBB-6A8D7B26EDB3%7d).
48. Campbell RJ, Dhalla IA, Gill SS, Bell CM. Implications of "not me" drugs for health systems: lessons from age related macular degeneration. BMJ 2012;344:e2941.
49. Annual report 2011. F. Hoffmann-La Roche, 2012:66 (available at www.roche.com/investors/annual-reports.htm).
50. Medicare Payment Advisory Commission. A data book: healthcare spending and the Medicare program. MedPAC, 2010 (available at www.medpac.gov/documents/ Jun10DataBookEntireReport.pdf).
51. Mitka M. Macular degeneration coverage. JAMA 2011;306:1073.
52. National Institute for Health and Clinical Excellence. NICE's report on the feasibility of appraising the use of bevacizumab (Avastin) to treat eye conditions. NICE, 2010 (available at: www.nice.org.uk/newsroom/pressreleases/ BevacizumabAvastinToTreatEyeConditions.jsp).
53. National Institute for Health and Clinical Excellence. Bevacizumab (Avastin) for eye conditions: Report of findings from a workshop held at NICE on 13 July 2010. www.nice.org.uk/media/AC2/3C/ BevacizumabEyeConditionsPrescopingReport.pdf.
54. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; published online 10 May.
55. Ferner R, Hughes DA, Aronson J. NICE and new: appraising innovation. BMJ 2010;340:245-7.
56. Pollack A. Doctors grow wary of Avastin for eye treatment. New York Times 2011 Oct 4. http://prescriptions.blogs.nytimes.com/2011/10/04/doctors-grow- wary-of-avastin-for-eye-treatment/.
57. Berkrot B, Pierson R. VA halts Avastin use for eye disease. Reuters (US edition) 2011 Sep 21. www.reuters.com/article/2011/09/21/us-roche-va- idUSTRE78K6F520110921.